Northwestern Mutual Wealth Management Co. Acquires Shares of 39,913 Danaher Corporation $DHR

Northwestern Mutual Wealth Management Co. bought a new position in shares of Danaher Corporation (NYSE:DHRFree Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 39,913 shares of the conglomerate’s stock, valued at approximately $7,603,000.

A number of other large investors have also made changes to their positions in DHR. BlackRock Inc. purchased a new stake in Danaher in the 2nd quarter valued at $10,492,520,000. Norges Bank purchased a new position in shares of Danaher during the 4th quarter worth $2,177,106,000. Generation Investment Management LLP acquired a new position in shares of Danaher during the 2nd quarter valued at about $1,287,949,000. Flossbach Von Storch SE purchased a new stake in shares of Danaher in the second quarter valued at about $747,260,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Danaher in the second quarter valued at about $712,875,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Citigroup began coverage on shares of Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price objective for the company. Royal Bank Of Canada increased their price target on shares of Danaher from $200.00 to $215.00 and gave the company an “outperform” rating in a research note on Wednesday, July 22nd. Piper Sandler started coverage on shares of Danaher in a research note on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target for the company. HSBC cut their price target on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Finally, Wells Fargo & Company decreased their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $228.91.

Read Our Latest Stock Report on Danaher

Danaher Stock Up 0.3%

Danaher stock opened at $219.42 on Monday. The company has a market capitalization of $154.25 billion, a PE ratio of 38.97, a price-to-earnings-growth ratio of 2.72 and a beta of 0.78. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The firm has a 50 day moving average price of $195.80 and a 200 day moving average price of $192.40.

Danaher (NYSE:DHRGet Free Report) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same period in the prior year, the firm earned $0.77 earnings per share. The firm’s revenue was up 5.5% compared to the same quarter last year. Research analysts expect that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Company Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Recommended Stories

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.